Clinical trial
A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease
NCT02229955 is registered in ClinicalTrials.gov with Hanlim Pharm. Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind Phase Ⅲ Study of Cyclosporine Ophthalmic Soution Group and Cyclosporine Ophthalmic Suspension Group 12 Weeks After Treatment in Moderate to Severe Dry Eye Disease
- Lead sponsor
- Hanlim Pharm. Co., Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2013
- Completion date
- July 31, 2014
- Enrollment
- 86 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.